Stock DERM JOURNEY MEDICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Journey Medical Corporation

Equities

DERM

US48115J1097

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
3.9 USD +2.63% Intraday chart for Journey Medical Corporation +8.33% -32.29%
May. 13 Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024
May. 13 Journey Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alliance Global Partners Starts Coverage on Journey Medical With Buy Rating, $8.50 Price Target
MT
B. Riley Lifts Journey Medical's PT to $8 From $6 After US FDA Gives Green Light for DFD-29's Year-End 2023 Filing, Keeps Buy Rating
MT
B. Riley Raises Journey Medical's PT to $6 From $3 On 'Impressive' Results From DFD-29 Study in Moderate to Severe Papulopustular Rosacea, Keeps Buy Rating
MT
B. Riley Cuts Journey Medical's Price Target to $3 From $6, Keeps Buy Rating
MT
B. Riley Lowers Journey Medical's Price Target to $6 From $10 After Q3 Topline Miss on Generic Competition, Keeps Buy Rating
MT
B. Riley Lowers Journey Medical's Price Target to $10 from $14, Keeps Buy Rating
MT
Cantor Fitzgerald Reinstates Journey Medical at Overweight with $9 Price Target
MT
Roth Capital Starts Journey Medical at Buy With $15 Price Target
MT
B. Riley Starts Journey Medical at Buy with $14 PT, Says Well-Positioned for Revenue, Earnings Growth
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DERM Stock
  4. News Journey Medical Corporation
  5. Analyst Reco.